Table 3.

Univariate Analyses of Recurrence-Free Survival and Disease-Specific Survival in 259 Patients with Hepatocellular Carcinomas

Variable	Recurrence-free survival		Disease-specific survival
	HR (95% CI)	p-value	HR (95% CI)	p-value
Age (≤55 vs >55), yr	1.01 (0.76–1.36)	0.926	0.95 (0.64–1.41)	0.794
Gender (female vs male)	1.01 (0.70–1.45)	0.961	1.31 (0.77–2.20)	0.318
Tumor size (≤5.0 vs >5.0), cm	1.64 (1.22–2.21)	0.001	2.53 (1.71–3.74)	<0.001
Edmondson grade (I+II vs III)	1.95 (1.40–2.71)	<0.001	2.21 (1.45–3.37)	<0.001
Microvascular invasion (no vs yes)	2.15 (1.59–2.90)	<0.001	3.09 (1.99–4.81)	<0.001
Major portal vein invasion (no vs yes)	3.84 (2.07–7.09)	<0.001	6.43 (3.30–12.52)	<0.001
Intrahepatic metastasis (no vs yes)	4.38 (3.17–6.06)	<0.001	5.97 (3.99–8.92)	<0.001
Multicentric occurrence (no vs yes)	1.59 (0.86–2.92)	0.138	0.88 (0.32–2.39)	0.799
AJCC T-stage (1 vs 2+3+4)	2.24 (1.65–3.03)	<0.001	3.25 (2.06–5.11)	<0.001
BCLC stage (0+A vs B+C)	2.05 (1.53–2.74)	<0.001	3.45 (2.28–5.20)	<0.001
Albumin level (>3.5 vs ≤3.5), g/dL	1.89 (1.23–2.90)	0.004	2.47 (1.46–4.17)	0.001
AFP level (≤200 vs >200), ng/mL*	1.58 (1.18–2.13)	0.002	1.47 (0.99–2.19)	0.059
Etiology (nonviral vs viral)	2.06 (1.25–3.39)	0.005	1.64 (0.85–3.16)	0.137
Liver cirrhosis (no vs yes)	1.34 (1.00–1.79)	0.047	1.11 (0.75–1.64)	0.611
RRM2 expression (low vs high)	1.68 (1.13–2.49)	0.011	3.22 (1.56–6.63)	0.002

HR, hazard ratio; CI, confidence interval; AJCC, American Joint Committee on Cancer; BCLC, Barcelona Clinic Liver Cancer; AFP, α-fetoprotein; RRM2, ribonucleotide reductase subunit M2.

^*Data for 10 patients were unavailable.